8-K: Syros Pharmaceuticals Amends Loan Agreement with Oxford Finance Amidst Trial Failure

Syros Pharmaceuticals has entered into a fifth amendment to its loan agreement with Oxford Finance, securing a forbearance period while it pursues a sale of assets to repay its debt.

Summary

• Syros Pharmaceuticals experienced a default on its loan agreement with Oxford Finance due to the failure of its SELECT-MDS-1 Phase 3 trial.
• Oxford Finance issued a notice demanding immediate repayment of approximately $43.7 million.
• Syros made a partial payment of $33.5 million, leaving a remaining balance.
• A fifth amendment to the loan agreement was reached, granting Syros a forbearance period until February 28, 2025.
• As part of the agreement, Syros granted Oxford a first priority security interest in its intellectual property.
• Syros is required to pursue a sale of assets to repay the debt by February 28, 2025.
• The company must operate under a wind-down budget approved by Oxford and prepay obligations with any refunds, including an anticipated $2.4 million Employee Retention Credit.
• Syros will also pay a $100,000 success fee to Oxford upon certain liquidity events.

Sentiment

Score: 2

Explanation: The document indicates a significant negative event with the loan default and forced asset sale, suggesting a very challenging situation for the company.

Positives

• Syros secured a forbearance period, avoiding immediate enforcement of remedies by Oxford Finance.
• The company has time until February 28, 2025, to pursue a sale of assets to repay its debt.
• The agreement allows for an orderly wind-down of operations to maximize asset value.

Negatives

• The company defaulted on its loan agreement due to a failed clinical trial.
• Syros is now required to sell assets to repay its debt.
• The company is operating under a wind-down budget, limiting its expenditures.
• Syros has granted a first priority security interest in its intellectual property to Oxford Finance.

Risks

• The company may not be able to complete a sale of assets by the February 28, 2025 deadline.
• The sale of assets may not generate sufficient proceeds to repay all obligations to Oxford Finance.
• Failure to comply with the terms of the amended loan agreement could result in Oxford exercising its remedies.
• The wind-down of operations may negatively impact the company's value and future prospects.

Future Outlook

Syros Pharmaceuticals is focused on selling assets to repay its debt to Oxford Finance by February 28, 2025, while operating under a wind-down budget.

Management Comments

• Borrower has requested that, rather than exercise the remedies available to them at the present time, Collateral Agent and Lenders, subject to the terms of this Amendment, refrain from exercising their remedies so Borrower may conduct an orderly wind-down of its operations so as to maximize the value of Borrowers assets as they are liquidated for the benefit of all of its stakeholders, including Lenders.

Industry Context

The failure of a Phase 3 trial and subsequent financial restructuring highlights the risks inherent in the biotechnology industry, where clinical trial outcomes can significantly impact a company's financial stability.

Comparison to Industry Standards

• The situation is similar to other biotech companies that have faced financial difficulties after clinical trial failures, such as Agenus Inc. which had to restructure debt after a trial setback.
• The requirement to sell assets to repay debt is a common outcome for companies in this situation, similar to what happened with companies like Omeros Corporation after facing financial challenges.
• The granting of a first priority security interest in intellectual property is a typical measure taken by lenders to secure their position in such circumstances, as seen in other biotech restructurings.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial distress and forced asset sale.
• Employees may be impacted by the wind-down of operations and potential job losses.
• Creditors, particularly Oxford Finance, are prioritized in the repayment process.
• Customers and suppliers may experience disruptions due to the company's restructuring.

Next Steps

• Syros will engage a Sale Advisor to facilitate the sale of assets.
• The company will adhere to fixed deadlines for the sale process.
• Syros will operate under a wind-down budget approved by Oxford Finance.
• The company will provide biweekly cash-flow reports to Oxford Finance and Lenders.

Key Dates

Keywords

loan agreement, default, forbearance, asset sale, intellectual property, wind-down, Oxford Finance, Syros Pharmaceuticals, debt repayment, clinical trial failure